Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD
At the Aging Research and Drug Development conference, Novo Nordisk and Eli Lilly presented early data that their GLP‑1 based medicines, already approved for diabetes and obesity, produced biomarker changes consistent with slower biological aging. The results stem from small‑scale studies and suggest potential anti‑aging effects, though researchers cautioned that larger trials are required to confirm the findings.